中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
Chinese Journal of Biochemical Pharmaceutics
2015年
10期
35-37
,共3页
阿仑膦酸钠%骨质疏松性脊柱压缩性骨折%椎体成形术
阿崙膦痠鈉%骨質疏鬆性脊柱壓縮性骨摺%椎體成形術
아륜련산납%골질소송성척주압축성골절%추체성형술
alendronate%osteoporotic vertebral compression fractures%vertebroplasty
目的 研究阿仑膦酸钠治疗骨质疏松性脊柱压缩性骨折(osteoporotic vertebral compression fractures,OVCF)椎体成形术后残余疼痛的早期疗效.方法 选取2013年9月~2014年10月期间浙江省磐安县人民医院收治的62例OVCF患者,按照入院顺序将患者分为观察组和对照组,每组各31例.所有患者在术后1 d均给予碳酸钙D3片,观察组患者在此基础上使用阿仑磷酸钠.比较2组患者治疗前和治疗半个月、1个月及2个月后的疼痛程度评分,观察2组患者的疼痛改善情况,比较2组患者治疗前后的活动能力评分、止痛药使用及骨密度情况.结果 观察组患者术后1个月的疼痛程度评分为(0.8 ±0.4)分,术后2个月的疼痛评分为(0.4 ±0.2)分,均显著低于对照组[(1.6 ±0.7)分;(1.1 ±0.8)分,P<0.05];观察组患者的疼痛优良率为83.87%,显著高于对照组的58.06%(P<0.05);治疗后,观察组患者的活动能力评分为(1.13 ±0.53)分,止痛药使用情况为(0.44 ±0.07)次/d,均显著低于对照组(1.79 ±0.89)分,(0.89 ±0.12)次/d(P<0.05),但骨密度水平(5.78 ±1.02)%显著高于对照组(3.21 ±0.79)%(P<0.05).结论 阿仑膦酸钠治疗OVCF椎体成形术后残余疼痛具有较好的早期疗效,并且不良反应少,安全性相对较高.
目的 研究阿崙膦痠鈉治療骨質疏鬆性脊柱壓縮性骨摺(osteoporotic vertebral compression fractures,OVCF)椎體成形術後殘餘疼痛的早期療效.方法 選取2013年9月~2014年10月期間浙江省磐安縣人民醫院收治的62例OVCF患者,按照入院順序將患者分為觀察組和對照組,每組各31例.所有患者在術後1 d均給予碳痠鈣D3片,觀察組患者在此基礎上使用阿崙燐痠鈉.比較2組患者治療前和治療半箇月、1箇月及2箇月後的疼痛程度評分,觀察2組患者的疼痛改善情況,比較2組患者治療前後的活動能力評分、止痛藥使用及骨密度情況.結果 觀察組患者術後1箇月的疼痛程度評分為(0.8 ±0.4)分,術後2箇月的疼痛評分為(0.4 ±0.2)分,均顯著低于對照組[(1.6 ±0.7)分;(1.1 ±0.8)分,P<0.05];觀察組患者的疼痛優良率為83.87%,顯著高于對照組的58.06%(P<0.05);治療後,觀察組患者的活動能力評分為(1.13 ±0.53)分,止痛藥使用情況為(0.44 ±0.07)次/d,均顯著低于對照組(1.79 ±0.89)分,(0.89 ±0.12)次/d(P<0.05),但骨密度水平(5.78 ±1.02)%顯著高于對照組(3.21 ±0.79)%(P<0.05).結論 阿崙膦痠鈉治療OVCF椎體成形術後殘餘疼痛具有較好的早期療效,併且不良反應少,安全性相對較高.
목적 연구아륜련산납치료골질소송성척주압축성골절(osteoporotic vertebral compression fractures,OVCF)추체성형술후잔여동통적조기료효.방법 선취2013년9월~2014년10월기간절강성반안현인민의원수치적62례OVCF환자,안조입원순서장환자분위관찰조화대조조,매조각31례.소유환자재술후1 d균급여탄산개D3편,관찰조환자재차기출상사용아륜린산납.비교2조환자치료전화치료반개월、1개월급2개월후적동통정도평분,관찰2조환자적동통개선정황,비교2조환자치료전후적활동능력평분、지통약사용급골밀도정황.결과 관찰조환자술후1개월적동통정도평분위(0.8 ±0.4)분,술후2개월적동통평분위(0.4 ±0.2)분,균현저저우대조조[(1.6 ±0.7)분;(1.1 ±0.8)분,P<0.05];관찰조환자적동통우량솔위83.87%,현저고우대조조적58.06%(P<0.05);치료후,관찰조환자적활동능력평분위(1.13 ±0.53)분,지통약사용정황위(0.44 ±0.07)차/d,균현저저우대조조(1.79 ±0.89)분,(0.89 ±0.12)차/d(P<0.05),단골밀도수평(5.78 ±1.02)%현저고우대조조(3.21 ±0.79)%(P<0.05).결론 아륜련산납치료OVCF추체성형술후잔여동통구유교호적조기료효,병차불량반응소,안전성상대교고.
Objective To study the efficacy of alendronate in treatment of postoperative residual pain with osteoporotic vertebral compression fractures(OVCF) of vertebroplasty.Methods 62 patients with OVCF from September 2013 to October 2014 were divided into observation group and control group, each had 31 cases.All patients were given calcium carbonate D3 tablets 1 day after surgery, observation group were given alendronate on this basis.The degree of pain score between two groups pre-and post-treatment two weeks, one month, two months were observed and compared.Pain improvement in two groups were observed, and activity ability score, painkiller use and bone mineral density between two groups pre-and post-treatment were compared.Results The pain scores in observation group a month postoperative was (0.8 ±0.4) points and (0.4 ±0.2) points after two months, were significantly lower than those in control group[(1.6 ±0.7) points, (1.1 ±0.8) points, P<0.05].The excellent rate of pain improvement in observation group(83.87%) was significantly higher than that in control group (58.06%, P <0.05) .After treatment, activity ability score in observation group was (1.13 ±0.53) points and painkiller usage was (0.44 ±0.07) times per day, all significantly lower than those in control group [(1.79 ±0.89) points, (0.89 ±0.12) times per day, P<0.05].BMD level in observation group was (5.78 ±1.02)%, higher than that in control group[(3.21 ±0.79)%, P<0.05].Conclusion Alendronate in treatment of osteoporotic vertebral compression fractures vertebroplasty postoperative residual pain has good early outcome and low adverse reactions, and security is relatively high.
